The Phase 2 SANRECO topline readout for divesiran (PV) expected in August 2026 is the dominant catalyst. The narrowing loss and $72.1M cash position suggest manageable burn, but the company remains pre-commercialization. Traders should position for binary outcome at data readout; if positive, could unlock partner interest and re-rate the stock. If negative, the stock likely retraces to pre-pipeline-optimism levels.
Price Chart
Executive Summary
Silence Therapeutics reported Q2 2026 net loss of $12.3M ($0.09 per share), narrower than the $27.4M loss in Q2 2025 and ahead of the $0.11 consensus. Cash burn slowed as R&D costs dropped 48% YoY to $9.1M. The key catalyst is the upcoming Phase 2 SANRECO topline readout for divesiran in polycythemia vera expected in August 2026, which will determine the stock's near-term trajectory.
Key Financial Metrics
Key Facts
- Net loss of $12.3M ($0.09/share) vs $27.4M ($0.19/share) in Q2 2025 — narrower loss beats consensus of $0.11 loss
- Revenue $0.2M vs $0.4M in Q2 2025 (AstraZeneca collaboration) — no consensus revenue figure available for comparison
- Cash and cash equivalents $72.1M as of June 30, 2026, up from $11.3M at Dec 31, 2025 (no new financings cited; likely reflects timing of R&D benefit receivable and cash burn)
- R&D expenses fell 48% YoY to $9.1M (from $17.6M) due to zerlasiran Phase 3 readiness completion and reduced personnel costs
- Phase 2 SANRECO trial (divesiran) for polycythemia vera patient dosing completed June 2026; topline results on-track for August 2026 — binary catalyst
- SLN312 (AZD1705) Phase 1 results presented at EAS 2026; two preclinical programs (SLN365, SLN098) targeting IND filing in 2027
- No guidance or revenue/earnings estimates provided for upcoming periods
Financial Impact
Narrower-than-expected loss of $12.3M vs consensus EPS of $0.11 loss (approximately $15.4M) — beats on EPS but revenue was less than half of prior quarter's $0.4M; cash position $72.1M provides runway through upcoming Phase 2 catalyst
Risk Factors
- Phase 2 SANRECO trial failure or underwhelming efficacy would materially depress the stock given divesiran is the lead candidate
- Revenue from AstraZeneca collaboration is minimal and unpredictable; company is entirely dependent on pipeline advancement
- No approved products; ongoing net losses with no clear path to profitability without a partnership or commercialization event
- Cash burn of ~$12-15M/quarter implies roughly 4-5 quarters of runway at $72.1M; may need to raise capital if pipeline timelines slip
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341240 |
| Document: d162225d8k.htm | 0001193125-26-341240 |
| Document: 0001193125-26-341240-index-headers.html | 0001193125-26-341240 |
| Document: 0001193125-26-341240-index.html | 0001193125-26-341240 |
| Document: 0001193125-26-341240.txt | 0001193125-26-341240 |
| 8-K Data (Synthetic) | 0001193125-26-341240 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 424B5 | $14.72 $13.55 | ▲ +7.95% | ▲ +6.89% | $10.55 (+28.33%) |
Aug 10, 2026 7w ago | 8-K | $15.43 $13.69 | ▼ −11.28% | ▼ −10.36% | $10.55 (−31.63%) |
Aug 10, 2026 7w ago | 8-K | $15.43 $13.69 | ▼ −11.28% | ▼ −10.36% | $10.55 (−31.63%) |
Jun 23, 2026 14w ago | 8-K | $9.16 $11.83 | ▲ +29.15% | ▲ +27.22% | $10.55 (+15.17%) |
Mar 5, 2026 30w ago | 8-K | $5.50 $5.94 | ▲ +8.00% | ▲ +11.79% | $10.55 (+91.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access